How to buy Ayala Pharmaceuticals shares | $12.14

Own Ayala Pharmaceuticals shares in just a few minutes. Share price changes are updated daily.

Updated

Fact checked
Ayala Pharmaceuticals logo

Ayala Pharmaceuticals, Inc (AYLA) is a leading biotechnology business based in the US. It opened the day at $12.29 after a previous close of $12.21. During the day the price has varied from a low of $11.7 to a high of $12.4. The latest price was $12.14 (25 minute delay). Ayala Pharmaceuticals is listed on the NASDAQ and employs 31 staff. All prices are listed in US Dollars.

How to buy shares in Ayala Pharmaceuticals

  1. Choose a platform. If you're a beginner, our share-dealing table below can help you choose.
  2. Open your account. You'll need your ID, bank details and national insurance number.
  3. Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
  4. Search the platform for stock code: AYLA in this case.
  5. Research Ayala Pharmaceuticals shares. The platform should provide the latest information available.
  6. Buy your Ayala Pharmaceuticals shares. It's that simple.
The whole process can take as little as 15 minutes.

Ayala Pharmaceuticals share price

Use our graph to track the performance of AYLA stocks over time.

Ayala Pharmaceuticals shares at a glance

Information last updated 2020-10-06.
Open$12.29
High$12.4
Low$11.7
Close$12.14
Previous close$12.21
Change $-0.07
Change % -0.573%
Volume 5,121
Information last updated 2020-12-27.
52-week range$8.62 - $16.5
50-day moving average $10.8721
200-day moving average $11.6628
Wall St. target price$21.6
Dividend yield N/A (0%)
Earnings per share (TTM) N/A
Promoted
eToro Free Stocks

Invest in Ayala Pharmaceuticals shares with 0% commission

Other fees may apply. Your capital is at risk.

  • Unlimited trades, with no dealing charges or management fees
  • If your trades get copied you can earn extra money
  • Create an account today in a few minutes

Share dealing platform comparison

Table: sorted by promoted deals first
Data indicated here is updated regularly
Name Product Price per trade Frequent trader rate Platform fees Brand description
Fineco
£2.95
£2.95
Zero platform fee
Your first 100 trades are free with Fineco, T&Cs apply.
Fineco Bank is good for share traders and investors looking for a complete platform and wide offer. Capital at risk.
eToro Free Stocks
0% commission, no markup, no ticket fee, no management fee
N/A
Withdrawal fee & GDP to USD deposit conversion
Capital at risk. 0% commission but other fees may apply.
Stake
£0
£0
Zero platform fee
Join and receive a free share worth up to £100
Access unlimited commission-free trading on 3,800+ US stocks and ETFs with Stake. Capital at risk.
IG
0% commission on US shares, and £3 on UK shares
From £5
£0 - £24 per quarter
IG is good for experienced traders, and offers learning resources for beginners, all with wide access to shares, ETFs and funds. Capital at risk.
Degiro Share Dealing
£1.75 + 0.022% (max £5.00)
£1.75 + 0.022% (max £5.00)
Portfolio transfer fees (in & out)
Degiro is widely seen as one of the best low-cost share brokers, for people who are looking to trade regularly. Capital at risk.
Hargreaves Lansdown Fund and Share Account
£11.95
£5.95
No fees
Hargreaves Lansdown is the UK's number one platform for private investors, with the depth of features you'd expect from an established platform. Capital at risk.
Interactive Investor
From £7.99 on the Investor Service Plan
From £7.99 on the Investor Service Plan
No transfer fees or exit fees. £9.99 a month on the Investor Service Plan
Open an ISA, Trading Account or SIPP you will get £100 of free trades to buy or sell any investment (new customers only).
Interactive Investor offers everything most investors need. Its flat fees makes it pricey for small portfolios, but cheap for big ones. Capital at risk.
loading

Compare up to 4 providers

Data indicated here is updated regularly
Name Product Minimum deposit Maximum annual fee Price per trade Brand description
Interactive Investor stocks and shares ISA
Any lump sum or £25 a month
£119.88
£7.99
Interactive Investor offers everything most investors need. Its flat fees makes it pricey for small portfolios, but cheap for big ones. Capital at risk.
Hargreaves Lansdown stocks and shares ISA
£100
0.45%
£11.95
Hargreaves Lansdown is the UK's biggest wealth manager. It's got everything you'll need, from beginners to experienced investors. Capital at risk.
Nutmeg stocks and shares ISA
£100
0.75%
£0
Nutmeg offers three types of portfolios. Choose the one that goes with your investment style. Capital at risk.
Moneyfarm stocks and shares ISA
£1500
0.75%
£0
Capital at risk.
Saxo Markets stocks and shares ISA
No minimum deposit requirement
0.12%
£8.00
Saxo Markets offers a wide access to a range of stocks, ETFs and funds. Capital at risk.
AJ Bell stocks and shares ISA
£500
0.25%
£9.95
AJ Bell is a good all-rounder for people who to choose between shares, funds, ISAs and pensions. Capital at risk.
Fidelity stocks and shares ISA
£1000 or a regular savings plan from £50
0.35%
£10.00
Fidelity is another good all-rounder, offering a good package at a decent price. Not suited for trading shares. Capital at risk.
Legal & General stocks and shares ISA
Legal & General stocks and shares ISA
£100 or £20 a month
0.61%
N/A
Legal & General is a big financial services company which offers insurance, lifetime mortgage, pensions and stocks and shares ISAs. Capital at risk.
loading

Compare up to 4 providers

Data indicated here is updated regularly
Name Product Minimum investment Choose from Annual fee Brand description
Interactive Investor Pension
Any lump sum or £25 a month
Over 3,000 funds
£10/month
interactive investor is a flat-fee platform, which makes it cost effective for larger portfolios. Capital at risk.
Moneyfarm Pension
£1,500 (initial investment)
7 funds
0.35%-0.75%
Moneyfarm has pensions that are matched against your risk appetite, goals and planned retirement date. Capital at risk.
AJ Bell Pension
£1,000
Over 2,000 funds
0.05-0.25%
AJ Bell has two different pension options, a self managed pension and one that is managed for you. Capital at risk.
PensionBee Pension
No minimum
7 funds
0.5% - 0.95%
Pension Bee is a newbie in the pension market. It helps consolidate your pension plans into one place. Capital at risk.
Hargreaves Lansdown Pension
£100 or £25 a month
2,500 funds
0-0.45%
Hargreaves Lansdown is the UK's biggest wealth manager. It's got three different retirement options. Capital at risk.
Saxo Markets Pension
Saxo Markets Pension
£10
Over 11,000 funds
No annual fee
Saxo Markets gives flexibility and control over your investment strategy. Capital at risk.
Penfold
Penfold
No minimum
4 portfolios
0.75-0.88%
Moneybox Pension
£1
3 funds
0.15% - 0.45% charged monthly
Manage your money with an easy-to-use Moneybox app. Capital at risk.
loading

Compare up to 4 providers

All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.

Is it a good time to buy Ayala Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Ayala Pharmaceuticals price performance over time

Historical closes compared with the last close of $12.14

1 week (2021-01-08) -3.68%
1 month (2020-12-18) 5.11%
3 months (2020-10-16) -7.68%
6 months (2020-07-17) -2.88%

Ayala Pharmaceuticals financials

Revenue TTM $3.1 million
Gross profit TTM $1 million
Return on assets TTM -46.93%
Return on equity TTM 0%
Profit margin 0%
Market capitalisation $150.1 million

TTM: trailing 12 months

How to short and sell Ayala Pharmaceuticals shares

  1. Create a CFD or spread betting account.
  2. Search for the stock code. E.g. "AYLA.US"
  3. Choose your position size.
  4. Select "sell" rather than "buy".
  5. Confirm your position and keep tabs on it. You may wish to set limits on your position.

There are currently 15,707 Ayala Pharmaceuticals shares held short by investors – that's known as Ayala Pharmaceuticals's "short interest". This figure is 23.9% up from 12,678 last month.

There are a few different ways that this level of interest in shorting Ayala Pharmaceuticals shares can be evaluated.

Ayala Pharmaceuticals's "short interest ratio" (SIR)

Ayala Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Ayala Pharmaceuticals shares currently shorted divided by the average quantity of Ayala Pharmaceuticals shares traded daily (recently around 16027.551020408). Ayala Pharmaceuticals's SIR currently stands at 0.98. In other words for every 100,000 Ayala Pharmaceuticals shares traded daily on the market, roughly 980 shares are currently held short.

However Ayala Pharmaceuticals's short interest can also be evaluated against the total number of tradable Ayala Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Ayala Pharmaceuticals's short interest could be expressed as 0.0025% of the tradable shares (for every 100,000 tradable Ayala Pharmaceuticals shares, roughly 3 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Ayala Pharmaceuticals.

Find out more about how you can short Ayala Pharmaceuticals stock.

Ayala Pharmaceuticals share dividends

We're not expecting Ayala Pharmaceuticals to pay a dividend over the next 12 months. However, you can browse other dividend-paying shares in our guide.

Win £500 to get your trading started

Subscribe to trending stock alerts for a chance to win

By submitting, you agree to the Finder Privacy and Cookies Policy and Terms of Use

Ayala Pharmaceuticals overview

Ayala Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company's lead product candidate is AL101, which is an intravenous injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma for patients bearing Notch-activating mutations. It is also involved in developing AL102, an oral injectable small molecule GSI that is in Phase I clinical trial for the treatment of desmoid tumors. Ayala Pharmaceuticals, Inc. has a collaboration agreement with Novartis International Pharmaceutical Limited to develop AL102 for the treatment of multiple myeloma. The company was founded in 2017 and is based in Rehovot, Israel.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site